Amgen's US Biosimilar Launches Are Off To A Steady Start, With A Big Coverage Decision
Executive Summary
United HealthCare agreed to cover Mvasi and Kanjinti in a preferred position. Amgen VP-oncology sales & marketing Susan Logan talked to Scrip about the company's first US biosimilar launches.
You may also be interested in...
Amgen Sees A Vibrant US Biosimilars Market
Biosimilar executives Leah Christl and Chad Pettit see reasons for optimism in the US market as new launches and sales begin to add up. Amgen’s portfolio is annualizing at $1bn as of the fourth quarter.
Amgen Sees A Vibrant Biosimilars Market As Its Business Pushes Into Blockbuster Territory
Biosimilar executives Leah Christl and Chad Pettit see reasons for optimism in the US market as new launches and sales begin to add up. Amgen’s portfolio is annualizing at $1bn as of the fourth quarter.
Amgen’s Q3 Sales Beat Consensus, But Two Key New Drugs Fell Short
Revenue from migraine prophylaxis Aimovig shrank from Q2 levels, while cholesterol-lowering Repatha volume increased, but sales came in below consensus.